Rhumbline Advisers Icosavax, Inc. Transaction History

Rhumbline Advisers

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	BUY	$5.95 - $15.79 $10,513 - $27,900	1,767 Added 4.33%	42,538 $670,000
Q3 2023 Nov 09, 2023	BUY	$7.22 - $10.05 $9,999 - $13,919	1,385 Added 3.52%	40,771 $315,000
Q2 2023 Aug 08, 2023	BUY	$4.89 - $10.57 $23,207 - $50,165	4,746 Added 13.7%	39,386 $391,000
Q1 2023 May 11, 2023	BUY	$5.62 - $11.51 $3,490 - $7,147	621 Added 1.83%	34,640 $201,000
Q4 2022 Feb 14, 2023	BUY	$2.32 - $10.97 $3,280 - $15,511	1,414 Added 4.34%	34,019 $270,000
Q3 2022 Nov 10, 2022	BUY	$3.09 - $9.21 $5,481 - $16,338	1,774 Added 5.75%	32,605 $103,000
Q2 2022 Aug 11, 2022	BUY	$5.7 - $10.33 $59,673 - $108,144	10,469 Added 51.41%	30,831 $177,000
Q1 2022 May 12, 2022	BUY	$4.41 - $22.5 $35,601 - $181,642	8,073 Added 65.69%	20,362 $143,000
Q4 2021 Feb 10, 2022	BUY	$21.07 - $34.98 $5,562 - $9,234	264 Added 2.2%	12,289 $281,000
Q3 2021 Nov 12, 2021	BUY	$24.85 - $40.25 $298,821 - $484,006	12,025 New	12,025 $356,000

1.37M

Ticker ICVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,885,200
Description
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical tri...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.